Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Enliven Therapeutics Inc. (ELVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ELVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40
1 Year Target Price $40
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.41% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.32B USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 8 | Beta 0.95 | 52 Weeks Range 13.30 - 30.03 | Updated Date 07/13/2025 |
52 Weeks Range 13.30 - 30.03 | Updated Date 07/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.36% | Return on Equity (TTM) -31.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1035141000 | Price to Sales(TTM) - |
Enterprise Value 1035141000 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 58990200 | Shares Floating 30393498 |
Shares Outstanding 58990200 | Shares Floating 30393498 | ||
Percent Insiders 4.75 | Percent Institutions 88.57 |
Upturn AI SWOT
Enliven Therapeutics Inc.
Company Overview
History and Background
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors for the treatment of cancer. Founded in 2018, the company aims to address unmet needs in specific cancer patient populations. The company went public in 2023.
Core Business Areas
- Precision Oncology: Enliven focuses on developing targeted therapies that address specific genetic drivers of cancer. Their lead product candidates are designed to selectively inhibit specific kinases implicated in cancer growth and resistance.
- Small Molecule Drug Development: Enliven's expertise lies in the discovery and development of small molecule inhibitors, which are designed to be orally bioavailable and target intracellular kinases.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, oncology, and finance. The company structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- ELVN-3231: A highly selective, potent, and orally bioavailable small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (mIDH1) enzyme. Currently in clinical development. Competitors include Agios Pharmaceuticals (acquired by Servier) with Tibsovo.
- ELVN-3106: A potent and selective small molecule inhibitor of the EGFR exon 20 insertion mutations. Currently in clinical development. Competitors include TAKEDA with EXKIVITY (mobocertinib).
Market Dynamics
Industry Overview
The oncology market is a large and growing market, driven by an aging population, advances in cancer diagnostics, and the development of new targeted therapies. Precision oncology is a rapidly evolving field, with increasing emphasis on personalized medicine based on genetic profiling of tumors.
Positioning
Enliven Therapeutics is positioned as a precision oncology company focused on developing innovative kinase inhibitors for specific cancer targets. Their competitive advantage lies in their expertise in small molecule drug development and their focus on addressing unmet needs in genetically defined cancer populations.
Total Addressable Market (TAM)
The global oncology market is expected to reach over $500 billion by 2030. Enliven is positioned to capture a share of this market by developing targeted therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in kinase inhibitor development
- Focus on precision oncology and targeted therapies
- Lead product candidates with promising preclinical and clinical data
- Experienced management team
- Strong cash position from IPO
Weaknesses
- Early-stage clinical development, high risk of failure
- Reliance on a limited number of product candidates
- Competition from larger pharmaceutical companies
- High cash burn rate
Opportunities
- Potential for accelerated approval pathways for targeted therapies
- Expansion of pipeline through internal research and development or acquisitions
- Partnerships with larger pharmaceutical companies for clinical development and commercialization
- Expanding market for precision oncology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- AGIO
- TAK
- MRTX
Competitive Landscape
Enliven Therapeutics is a smaller player in a competitive market. Their advantages include their focus on specific cancer targets and their expertise in small molecule drug development. However, they face competition from larger pharmaceutical companies with more resources and established products.
Growth Trajectory and Initiatives
Historical Growth: As a recently IPO'd company, historical growth is primarily defined by preclinical and early clinical development progress.
Future Projections: Future growth is dependent on successful clinical development and regulatory approval of their lead product candidates. Analyst estimates will vary based on perceived probability of success.
Recent Initiatives: Focus on advancing ELVN-3231 and ELVN-3106 through clinical trials, expanding pipeline through internal research and development, and building strategic partnerships.
Summary
Enliven Therapeutics is an early-stage biopharmaceutical company with a focus on precision oncology. The company has promising lead product candidates in clinical development. However, it faces significant risks associated with clinical trials, regulatory hurdles, and competition from larger pharmaceutical companies. A strong cash position provides runway, but its future success hinges on clinical data and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Enliven Therapeutics Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | |
Full time employees 65 | |||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.